Glenmark opts for Horizon’s gene edited cell lines

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Milkos)
(Image: Getty/Milkos)

Related tags Glenmark Pharmaceuticals Horizon Discovery Cell line Monoclonal antibodies

Glenmark signs a full commercial license to utilize Horizon’s gene edited CHO cell lines to be added to the former’s biomanufacturing process.

The agreement sees Glenmark Pharmaceuticals gain access to Horizon Discovery’s glutamine synthetase knockout Chinese Hamster Ovary (CHO) K1 cell line.

Regarding its decision to opt for Horizon’s technology, Glenmark confirmed that the cell lines were able to deliver clones with ‘high levels of productivity’ and a ‘favorable stability’ when compared with its previous system during testing.

Martin Bertschinger, deputy director of cell sciences at Glenmark, said, “Incorporating this technology into our biomanufacturing processes enhances our ability to efficiently generate high quality cell lines.”

The Indian company has been scaling up its production of biologics in recent years, which has seen it open a facility in La Chaux-de-Fonds​, Switzerland, and to add second single-use production line​ to manufacture monoclonal antibodies (mAbs) and bispecific antibodies.

Glenmark holds four mAbs within its clinical pipeline, with the drug candidates being investigated within oncology and immunology.

Dirk Gewert, business unit director at Horizon Discovery, confirmed that the technology had been used by other companies to progress their clinical candidates towards commercialization.

“This proprietary solution has now been licensed to over 50 companies globally, which, together with a number of confirmed investigational new drug filings for products expressed in the cells, demonstrates increasing industry acceptance,”​ he commented.

Related topics Bio Developments Pipelines Cell lines

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us


View more